Compare Stocks → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CAPRNASDAQ:LBPHNASDAQ:NLTXNASDAQ:SYRS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$5.68+2.3%$5.87$2.68▼$8.22$180.69M4.06338,159 shs385,871 shsLBPHLongboard Pharmaceuticals$18.87+5.4%$19.80$3.60▼$28.15$733.67M1.25234,566 shs626,829 shsNLTXNeoleukin Therapeutics$37.60+10.5%$36.15$2.03▼$14.36$32.80M1.1150,104 shs138,019 shsSYRSSyros Pharmaceuticals$5.10+2.0%$5.23$2.09▼$8.17$136.31M1.75102,880 shs143,400 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-5.18%+8.40%+24.42%+25.39%LBPHLongboard Pharmaceuticals0.00%+0.37%-17.27%-11.57%+172.29%NLTXNeoleukin Therapeutics+10.49%+17.10%+6.24%+17.50%+135.00%SYRSSyros Pharmaceuticals0.00%+2.62%-1.92%-34.19%+32.47%Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPRCapricor Therapeutics1.1098 of 5 stars3.50.00.00.02.70.80.6LBPHLongboard Pharmaceuticals1.43 of 5 stars3.51.00.00.03.31.70.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASYRSSyros Pharmaceuticals4.1077 of 5 stars3.51.00.04.32.93.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics3.00Buy$21.75282.92% UpsideLBPHLongboard Pharmaceuticals3.00Buy$43.67131.41% UpsideNLTXNeoleukin TherapeuticsN/AN/AN/AN/ASYRSSyros Pharmaceuticals3.00Buy$14.00174.51% UpsideCurrent Analyst RatingsLatest SYRS, CAPR, LBPH, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/17/2024CAPRCapricor TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.005/15/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/14/2024CAPRCapricor TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.005/14/2024CAPRCapricor TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.005/14/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.005/7/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.005/3/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.005/3/2024LBPHLongboard PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $34.005/1/2024LBPHLongboard PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$36.004/25/2024CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/16/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$25.18M7.18N/AN/A$0.58 per share9.79LBPHLongboard PharmaceuticalsN/AN/AN/AN/A$8.07 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASYRSSyros Pharmaceuticals$9.94M13.71N/AN/A$0.56 per share9.11Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$22.29M-$0.87N/AN/AN/A-89.72%-231.68%-50.83%8/5/2024 (Estimated)LBPHLongboard Pharmaceuticals-$54.42M-$2.24N/AN/AN/AN/A-49.87%-46.04%8/1/2024 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASYRSSyros Pharmaceuticals-$164.57M-$5.01N/AN/AN/A-1,656.34%-395.36%-88.41%8/13/2024 (Estimated)Latest SYRS, CAPR, LBPH, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024SYRSSyros Pharmaceuticals-$0.89-$0.79+$0.10-$1.48$1.30 millionN/A 5/2/2024Q1 2024LBPHLongboard Pharmaceuticals-$0.48-$0.42+$0.06-$0.42N/AN/A3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million3/12/2024Q4 2023LBPHLongboard Pharmaceuticals-$0.60-$0.62-$0.02-$0.62N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/ALBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A1.571.57LBPHLongboard PharmaceuticalsN/A31.4331.43NLTXNeoleukin TherapeuticsN/A15.3315.33SYRSSyros Pharmaceuticals1.973.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%LBPHLongboard Pharmaceuticals63.28%NLTXNeoleukin Therapeutics52.37%SYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics12.00%LBPHLongboard Pharmaceuticals4.64%NLTXNeoleukin Therapeutics1.58%SYRSSyros Pharmaceuticals12.26%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor TherapeuticsN/A31.81 million27.99 millionOptionableLBPHLongboard Pharmaceuticals5038.88 million37.08 millionOptionableNLTXNeoleukin Therapeutics79.40 million9.25 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.45 millionOptionableSYRS, CAPR, LBPH, and NLTX HeadlinesRecent News About These CompaniesMay 31 at 4:26 AM | americanbankingnews.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Crosses Below 50-Day Moving Average of $5.25May 21, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $909,000 Holdings in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)May 17, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:SYRS)May 16, 2024 | marketbeat.comFY2026 Earnings Forecast for Syros Pharmaceuticals, Inc. Issued By Brookline Capital Management (NASDAQ:SYRS)May 16, 2024 | markets.businessinsider.comOptimistic Outlook for Syros Pharmaceuticals with Promising Clinical Trials and Regulatory AdvancementsMay 15, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Issues Earnings Results, Beats Estimates By $0.10 EPSMay 15, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Syros Pharmaceuticals (NASDAQ:SYRS)May 15, 2024 | markets.businessinsider.comHere's what Wall Street expects from Syros Pharmaceuticals's earningsMay 15, 2024 | finance.yahoo.comSyros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Syros Pharmaceuticals Inc Earnings CallMay 14, 2024 | msn.comSyros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77May 14, 2024 | msn.comSYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | businesswire.comSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 12, 2024 | marketbeat.comShort Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Drops By 22.0%May 7, 2024 | businesswire.comSyros to Participate in Upcoming Investor ConferencesMay 7, 2024 | businesswire.comSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024May 2, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Price Passes Below 50 Day Moving Average of $5.94May 1, 2024 | zacks.comAnalysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out forApril 10, 2024 | marketwatch.comSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for TamibaroteneApril 10, 2024 | zacks.comSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AMLApril 10, 2024 | zacks.comSyros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?New MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks You Can Buy Before They Become BigMay 6, 2024 8:00 AMView 3 Value Stocks You Can Buy Before They Become Big3 Stocks Nancy Pelosi Has Been BuyingMay 10, 2024 8:35 AMView 3 Stocks Nancy Pelosi Has Been Buying3 Affordable Stocks That Won’t Stay Down Much LongerMay 13, 2024 9:12 AMView 3 Affordable Stocks That Won’t Stay Down Much Longer3 Reasons Nvidia is on The Verge of a 4 Digit Stock PriceMay 17, 2024 8:39 AMView 3 Reasons Nvidia is on The Verge of a 4 Digit Stock PriceCanada Goose Flies Higher Driven By DTC GrowthMay 20, 2024 6:25 AMView Canada Goose Flies Higher Driven By DTC GrowthAll HeadlinesCompany DescriptionsCapricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Longboard PharmaceuticalsNASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Neoleukin TherapeuticsNASDAQ:NLTXNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.